Fycompa

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
IB/0068/G	This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters	02/05/2023	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
PSUSA/9255/ 202207	Periodic Safety Update EU Single assessment - perampanel	23/02/2023	27/04/2023	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/202207.
IA/0067	B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products	16/01/2023	n/a		
IAIN/0066	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	22/11/2022	n/a		
IAIN/0065	B.II.d.1.h - Change in the specification parameters and/or limits of the finished product - Update of the dossier to comply with the provisions of an updated general monograph of the Ph. Eur. for the finished product	22/11/2022	n/a		

IB/0063	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	24/08/2022	27/04/2023	SmPC, Labelling and PL	
PSUSA/9255/202107	Periodic Safety Update EU Single assessment - perampanel	24/02/2022	25/04/2022	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/202107.
N/0062	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/03/2022	27/04/2023	PL	
N/0060	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	10/09/2021	25/04/2022	PL	
IB/0058/G	This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.z - Stability of FP - Other variation	17/06/2021	25/04/2022	SmPC	To update section 6.3 of the Summary of Product Characteristics for Fycompa 0.5 mg/ml oral suspension (EU/1/12/776/024) from 2 years to 30 months.
IA/0059	B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)	03/06/2021	n/a		
PSUSA/9255/202007	Periodic Safety Update EU Single assessment - perampanel	25/02/2021	21/04/2021	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/202007.
IA/0057	A.7 - Administrative change - Deletion of manufacturing sites	10/03/2021	25/04/2022	Annex II and	

				PL	
IA/0056	A.7 - Administrative change - Deletion of manufacturing sites	07/01/2021	n/a		
II/0047	Extension of Indication to include the paediatric patients from 4 to 11 years of age for the adjunctive treatment of partial-onset seizures with or without secondary generalisation and from 7 to 11 years of age for the adjunctive treatment of primary generalised tonic-clonic seizures with idiopathic generalised epilepsy for Fycompa. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP version 4.5 has also been submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	17/09/2020	10/11/2020	SmPC and PL	Please refer to Scientific Discussion 'Fycompa-H-C-002434-II-0047
N/0052	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	09/07/2020	10/11/2020	PL	
IG/1263	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	24/06/2020	10/11/2020	Annex II and PL	
IG/1260/G	This was an application for a group of variations.	24/06/2020	10/11/2020	SmPC, Labelling and	

	A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place			PL	
PSUSA/9255/201907	Periodic Safety Update EU Single assessment - perampanel	27/02/2020	28/04/2020	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/201907.
IA/0051	B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method	25/10/2019	n/a		
IA/0049	B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material	20/10/2019	n/a		
IA/0048	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient	15/10/2019	n/a		
IB/0046/G	This was an application for a group of variations.	25/06/2019	n/a		

	B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation				
IAIN/0045/G	This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non-sterile medicinal products B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	27/03/2019	n/a		
PSUSA/9255/201807	Periodic Safety Update EU Single assessment - perampanel	14/02/2019	n/a		PRAC Recommendation - maintenance
IG/1044/G	This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release	22/01/2019	n/a		

	arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing				
IG/1008	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	30/11/2018	29/10/2019	Annex II and PL	
T/0040	Transfer of Marketing Authorisation	23/08/2018	21/09/2018	SmPC, Labelling and PL	
IAIN/0039	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	04/07/2018	n/a		
PSUSA/9255/201707	Periodic Safety Update EU Single assessment - perampanel	22/02/2018	23/04/2018	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/9255/201707.
N/0038	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/11/2017	30/01/2018	PL	
PSUSA/9255/201701	Periodic Safety Update EU Single assessment - perampanel	01/09/2017	n/a		PRAC Recommendation - maintenance
R/0035	Renewal of the marketing authorisation.	26/01/2017	06/04/2017		Based on the review of data on quality, safety and efficacy,

					the CHMP considered that the benefit-risk balance of Fycompa in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
II/0034/G	This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	23/02/2017	30/01/2018	SmPC	In a retrospective study of clinical practice, 51 patients with epilepsy who received perampanel as adjunctive treatment converted to perampanel monotherapy. The majority of these patients had a history of partial onset seizures. Of these, 14 patients (27%) reverted to adjunctive therapy in the following months. Thirty four (34) patients were followed up for at least 6 months and, of these, 24 patients (71%) remained on perampanel monotherapy for at least 6 months. Ten (10) patients were followed up for at least 18 months and, of these, 3 patients (30%) remained on perampanel monotherapy for at least 18 months. Withdrawal of a concomitant CYP450 3A enzyme inducer can be expected to increase plasma concentrations of perampanel and dose reduction may be required.
PSUSA/9255/ 201607	Periodic Safety Update EU Single assessment - perampanel	09/02/2017	n/a		PRAC Recommendation - maintenance
II/0030	Update of sections 5.1 and 5.2 of the SmPC to reflect the results from study E2007-G000-235. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	20/10/2016	06/04/2017	SmPC	A 19-week, randomised, double-blind, placebo-controlled study with an open-label extension phase (Study 235) was performed to assess the short-term effects on cognition of Fycompa (target dose range of 8 to 12 mg once daily) as adjunctive therapy in 133 (Fycompa n=85, placebo n=48) adolescent patients, ages 12 to less than 18 years old, with inadequately controlled partial-onset seizures. Cognitive function was assessed by the Cognitive Drug Research (CDR) System Global Cognition t-Score, which is a

					composite score derived from 5 domains testing Power of Attention, Continuity of Attention, Quality of Episodic Secondary Memory, Quality of Working Memory, and Speed of Memory. The mean change (SD) from baseline to end of double-blind treatment (19 weeks) in CDR System Global Cognition t-Score was 1.1 (7.14) in the placebo group and (minus) –1.0 (8.86) in the perampanel group, with the difference between the treatment groups in LS means (95% CI) = (minus) 2.2 (5.2, 0.8). There was no statistically significant difference between the treatment groups (p = 0.145). CDR System Global Cognition t-Scores for placebo and perampanel were 41.2 (10.7) and 40.8 (13.0), respectively at the baseline. For patients with perampanel in the open label extension (n = 112), the mean change (SD) from baseline to end of open-label treatment (52 weeks) in CDR System Global Cognition t-Score was (minus) 1.0 (9.91). This was not statistically significant (p = 0.96). After up to 52 weeks of treatment with perampanel (n = 114), no effect on bone growth was observed. No effects on weight, height and sexual development were seen following up to 104 weeks of treatment (n = 114).
X/0025	Annex I_2.(d) Change or addition of a new pharmaceutical form	21/07/2016	19/09/2016	SmPC, Labelling and PL	
PSUSA/9255/ 201601	Periodic Safety Update EU Single assessment - perampanel	02/09/2016	n/a		PRAC Recommendation - maintenance
IB/0031/G	This was an application for a group of variations.	04/05/2016	n/a		

	B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IB/0028	C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation	24/02/2016	19/09/2016	SmPC	
PSUSA/9255/ 201507	Periodic Safety Update EU Single assessment - perampanel	11/02/2016	n/a		PRAC Recommendation - maintenance
II/0023	Update of sections 4.5 and 5.2 in order to update the safety information based on the results of a mass balance study. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	19/11/2015	19/09/2016	SmPC	A human mass balance study which achieved good recovery of radioactivity and where samples were assessed for metabolite concentration throughout the time course of sample collection was completed Post Authorisation Measure (PAM) to address a key remaining gap “bridging” in vitro data and in vivo data with regards to the potential role of CYP1A2 in the metabolism of perampanel. The MAH submitted a procedure to update of sections 4.5 and 5.2 in order to update the safety information based on the results of a mass balance study.
II/0024/G	This was an application for a group of variations.	17/09/2015	n/a		

	B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method				
PSUSA/9255/ 201501	Periodic Safety Update EU Single assessment - perampanel	10/09/2015	n/a		PRAC Recommendation - maintenance
IA/0026	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	23/07/2015	n/a		
II/0016	Extension of indication to include a new indication for Fycompa for adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. Consequently, the MAH proposed an update of sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC. In addition, minor editorial changes and amendments to improve the clarity and readability of the information was implemented throughout the product information. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	21/05/2015	22/06/2015	SmPC and PL	Please refer to the scientific discussion Fycompa EMEA/H/C/002434/II/0016 for further information.

IAIN/0022	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	26/05/2015	n/a		
IB/0021/G	This was an application for a group of variations. B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation B.II.f.1.e - Stability of FP - Change to an approved stability protocol	13/05/2015	22/06/2015	SmPC	
PSUSA/9255/201407	Periodic Safety Update EU Single assessment - perampanel	12/02/2015	n/a		PRAC Recommendation - maintenance
IA/0019	B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process	12/01/2015	n/a		
IB/0017	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	17/09/2014	n/a		
IB/0015/G	This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other	15/09/2014	22/06/2015	SmPC	

	variation				
PSUV/0014	Periodic Safety Update	11/09/2014	n/a		PRAC Recommendation - maintenance
PSUV/0010	Periodic Safety Update	06/02/2014	n/a		PRAC Recommendation - maintenance
IB/0013	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	20/12/2013	n/a		
IA/0012	B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to excipients	12/12/2013	n/a		
IAIN/0011	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	25/11/2013	n/a		
PSUV/0009	Periodic Safety Update	19/09/2013	13/11/2013	SmPC, Annex II and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUV/0009.
IG/0345	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	03/09/2013	n/a		
IA/0007	B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to	29/07/2013	n/a		

	excipients				
IAIN/0006	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	14/05/2013	n/a		
N/0005	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	31/01/2013	n/a		The Marketing Authorisation Holder (MAH) took the opportunity to undertake user testing for the three language package leaflet. It was confirmed that the text remains unchanged.
IB/0004	B.II.f.1.b.z - Stability of FP - Extension of the shelf life of the finished product - Other variation	14/11/2012	13/11/2013	SmPC	
IB/0003/G	This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished	27/09/2012	29/10/2012	SmPC, Labelling and PL	

	product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes				
IA/0002	B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms	05/09/2012	n/a		
IB/0001/G	This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size B.II.b.5.b - Change to in-process tests or limits	04/09/2012	n/a		

	applied during the manufacture of the finished product - Addition of a new tests and limits				